McIlrath & Eck’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Sell |
2,324
-69
| -3% | -$4.02K | 0.01% | 327 |
|
|
2025
Q4 | $129K | Buy |
2,393
+150
| +7% | +$7.22K | 0.01% | 213 |
|
|
2025
Q3 | $101K | Sell |
2,243
-88
| -4% | -$4.11K | 0.01% | 213 |
|
|
2025
Q2 | $108K | Buy |
2,331
+868
| +59% | +$42.6K | 0.01% | 193 |
|
|
2025
Q1 | $89.2K | Hold |
1,463
| – | – | 0.01% | 215 |
|
|
2024
Q4 | $82.7K | Sell |
1,463
-34
| -2% | -$1.9K | 0.01% | 216 |
|
|
2024
Q3 | $77.5K | Buy |
1,497
+2
| +0.1% | +$94 | 0.01% | 228 |
|
|
2024
Q2 | $62.1K | Hold |
1,495
| – | – | 0.01% | 246 |
|
|
2024
Q1 | $81.1K | Sell |
1,495
-365
| -20% | -$18.6K | 0.01% | 210 |
|
|
2023
Q4 | $95.4K | Sell |
1,860
-100
| -5% | -$5.25K | 0.02% | 173 |
|
|
2023
Q3 | $114K | Sell |
1,960
-29
| -1% | -$1.78K | 0.02% | 153 |
|
|
2023
Q2 | $127K | Sell |
1,989
-126
| -6% | -$8.45K | 0.03% | 142 |
|
|
2023
Q1 | $147K | Hold |
2,115
| – | – | 0.03% | 124 |
|
|
2022
Q4 | $152K | Buy |
2,115
+1
| +0% | +$75 | 0.04% | 117 |
|
|
2022
Q3 | $150K | Buy |
2,114
+25
| +1% | +$1.81K | 0.04% | 107 |
|
|
2022
Q2 | $161K | Buy |
2,089
+1
| +0% | +$76 | 0.05% | 94 |
|
|
2022
Q1 | $152K | Buy |
2,088
+15
| +0.7% | +$1.01K | 0.04% | 95 |
|
|
2021
Q4 | $129K | Sell |
2,073
-700
| -25% | -$41.1K | 0.03% | 112 |
|
|
2021
Q3 | $164K | Sell |
2,773
-199
| -7% | -$13.1K | 0.05% | 89 |
|
|
2021
Q2 | $199K | Hold |
2,972
| – | – | 0.06% | 84 |
|
|
2021
Q1 | $188K | Buy |
2,972
+1
| +0% | +$62 | 0.07% | 75 |
|
|
2020
Q4 | $184K | Sell |
2,971
-24
| -0.8% | -$1.48K | 0.07% | 66 |
|
|
2020
Q3 | $181K | Buy |
2,995
+101
| +3% | +$6.08K | 0.08% | 56 |
|
|
2020
Q2 | $170K | Sell |
2,894
-98
| -3% | -$5.86K | 0.08% | 54 |
|
|
2020
Q1 | $167K | Buy |
2,992
+254
| +9% | +$15.5K | 0.09% | 46 |
|
|
2019
Q4 | $176K | Buy |
2,738
+488
| +22% | +$27.9K | 0.08% | 52 |
|
|
2019
Q3 | $114K | Sell |
2,250
-143
| -6% | -$6.72K | 0.06% | 65 |
|
|
2019
Q2 | $114K | Hold |
2,393
| – | – | 0.06% | 61 |
|
|
2019
Q1 | $114K | Buy |
2,393
+50
| +2% | +$2.49K | 0.06% | 61 |
|
|
2018
Q4 | $122K | Sell |
2,343
-720
| -24% | -$38.7K | 0.08% | 56 |
|
|
2018
Q3 | $190K | Sell |
3,063
-189
| -6% | -$11.2K | 0.11% | 47 |
|
|
2018
Q2 | $180K | Sell |
3,252
-685
| -17% | -$37K | 0.11% | 47 |
|
|
2018
Q1 | $249K | Sell |
3,937
-1,100
| -22% | -$70.8K | 0.15% | 40 |
|
|
2017
Q4 | $309K | Buy |
+5,037
| New | +$315K | 0.18% | 36 |
|
Other funds holding BMY
McIlrath & Eck's BMY Position: Q1 2026 in Review
McIlrath & Eck reduced its Bristol-Myers Squibb (BMY) stake by 2.9% in Q1 2026, selling an estimated $4.02K and leaving 2,324 shares worth $141K. The position accounts for 0.01% of the portfolio, ranked #327.
McIlrath & Eck first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $309K in Q4 2017. 2,536 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- McIlrath & Eck held 2,324 shares of Bristol-Myers Squibb worth $141K as of Q1 2026.
- McIlrath & Eck sold 69 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.02K.
- Bristol-Myers Squibb made up 0.01% of McIlrath & Eck's portfolio in Q1 2026, its #327 holding.
- McIlrath & Eck first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- McIlrath & Eck's Bristol-Myers Squibb position peaked at $309K in Q4 2017.
- 2,536 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.